Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

Fig. 1

GDC-0152, LCL161 and doxorubicin impede the growth of subcutaneously implanted osteosarcomas in mice. Luciferase-expressing murine 1029H osteosarcoma cells were implanted subcutaneously into nude mice. 1 week after implantation the mice commenced the specified regimens of GDC-0152 (a-e), LCL161 (f) or doxorubicin (g). a, f, g Left panels: Primary tumor growth was monitored via bioluminescence, and tumor weights were measured post-mortem. One way ANOVAs with Sidak post-tests were used to estimate the probability that the drug treatments significantly affected tumor growth, as measured by bioluminescence at week 5, relative to saline treatment (*** P < 0.001; ** P < 0.01; * P < 0.05; ns P > 0.05 (colors of asterisks and “ns” labels; reflect the treatments, as indicated in the in-figure legends). Right panels: Mice were weighed each day to assess drug toxicity (n = 5–25, +/− SEM). b-e Tumor-bearing mice were treated with saline or GDC-0152 50 mg/kg/week. b Tumor responses were monitored by caliper measurements (left) or bioluminescence (right) at the indicated times (n = 3, +/− SEM). The differences between responses in saline and drug-treated mice were analyzed by a one way ANOVA with Sidak post-tests (*** P < 0.001). (C, D) 18F-FDG PET/MRI imaging was performed 30 days after the first treatment. c A cartoon, created using BioRender, illustrates the plane of transverse PET/MR images taken through 1029H osteosarcoma tumors (denoted by the arrow). d PET/MR imaging was performed on each mouse per treatment group (n = 3), oriented with the spine at the top and the femurs in the lower left and right parts of the images: left, positron emission tomography (PET); middle, magnetic resonance imaging (MRI); right column, PET/MRI overlay with white arrows indicating tumors . The color scale, which ranged from 0 to 1.5 SUV, indicates highest uptake of 18F-FDG in red and lowest uptake in black. The gray scale used for MR imaging, which ranged from 40.95 to 4095, indicates brightest signals from fat-containing soft tissues versus darker signals from water-containing soft tissues. (e) Mean standardized uptake values (SUV) of 18F-FDG-PET were determined by volume of interest (VOI) analysis, and tumor volumes were determined by VOI analysis of MRI images (n = 3, +/− SEM). Mann-Whitney non-parametric U-tests were used to calculate the significance of differences between treated and untreated mice * P < 0.05; ns P > 0.05

Back to article page